When was Fina Biosolutions founded?

Fina Biosolutions was founded in 2006 and raised its 1st funding round 14 years after it was founded.

Where is Fina Biosolutions located?

Fina Biosolutions is headquartered in Rockville, United States.

Who is the current CEO of Fina Biosolutions?

Andrew Lees of Fina Biosolutions. They are also an angel investors in 1 startup.

How many employees does Fina Biosolutions have?

As of Jul 01, 2024, the latest employee count at Fina Biosolutions is 1 - 10.

Is Fina Biosolutions a funded company?

Fina Biosolutions is a funded company, having raised a total of $3M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 20, 2020.

When was the latest funding round of Fina Biosolutions?

Fina Biosolutions' latest funding was a $***** Seed round on Oct 08, 2024, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $420M in funding in 2026 to date.

Where does Fina Biosolutions rank among its competitors?

Fina Biosolutions ranks 15th amongst 85 active competitors, of which 7 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Fina Biosolutions, which secured $3M in Oct, 2024.

Who are the top competitors of Fina Biosolutions?

Fina Biosolutions' top competitors include Nabla, Beryllium and Proteros. Among them, Fina Biosolutions secured the most recent funding round in October, 2024.

Fina Biosolutions - 2026 Company Profile, Team, Funding & Competitors

Fina Biosolutions is a seed company based in Rockville (United States), founded in 2006 by Andrew Lees. It operates as a Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets. Fina Biosolutions has raised $3M in funding from SK bioscience. The company has 85 active competitors, including 7 funded and 6 that have exited. Its top competitors include companies like Nabla, Beryllium and Proteros.

Company Details

Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets. The company provides bioconjugation services and products, assisting vaccine manufacturers in creating affordable conjugate vaccines. Core expertise lies in conjugation chemistry, bioconjugation, and conjugate vaccines. They offer a range of services including conjugation, protein services, and analytical services like multi-angle light scattering and immunoassay design. Products include carrier proteins like CRM197 and functionalized dextrans, including amino, fluorescent, and custom dextrans. They focus on making vaccine technology accessible, particularly in emerging markets, and offer consulting services to the Biotech and Vaccine industry. They also provide specialty immunoreagents and resources to support vaccine development and production.

Website: finabio.net
Social

Key Metrics

Founded Year

2006

Location

Rockville, United States

Stage

Seed

Total Funding

$3M in 4 rounds

Latest Funding Round

Seed, Oct 08, 2024, $*****

Investors

SK bioscience & 3 more

Ranked

15^th among 85 active competitors

Employee Count

1 - 10 as on Jul 01, 2024

Similar Companies

Nabla & 37 more

View Fina Biosolutions' full profile

Fina Biosolutions has raised a total funding of $3M over 4 rounds. Its first funding round was on Apr 20, 2020. Its latest funding round was a Seed round on Oct 08, 2024 for $*****. 1 investor participated in its latest round. Fina Biosolutions has 4 institutional investors.

Here is the list of recent funding rounds of Fina Biosolutions:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 08, 2024	5168822	Seed	3614573	2642970	9410238	8122212
Jan 23, 2024	4967877	Grant (prize money)	8498172	9377812	9710448	NIH
Jan 01, 2024	5531520	Grant (prize money)	7653688	5561392	8784786	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Fina Biosolutions's funding rounds and investors

The founders of Fina Biosolutions is Andrew Lees.

Here are the details of Fina Biosolutions' key team members:

Andrew Lees: Founder & CEO of Fina Biosolutions. They are also an angel investor in 1 startup.

View details of Fina Biosolutions's Founder profiles and Board Members

Fina Biosolutions' employee count trend

Fina Biosolutions has 1 - 10 employees as of Jul 24. Here is Fina Biosolutions's employee count trend over the years:

Employee count trend for Fina Biosolutions

Uncover Fina Biosolutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Fina Biosolutions include Nabla, Beryllium and Proteros. Here is the list of Top 10 competitors of Fina Biosolutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nabla 2020, Boston (United States), Series A	Provider of synthetic biology platform to identify functional proteins	$37M	Khosla Ventures, Zetta Venture Partners & 4 others	60/100
2nd	Beryllium 1999, Bedford (United Kingdom), Acquired	Boutique service provider offering a range of solutions for drug discovery	$11.5M	UCB, Gemini & 1 others	48/100
3rd	Proteros 1999, Germany, Early Stage	Provider of structure-based early-stage drug discovery services and technology platform	$13.2M	Inflexion, BayBG	46/100
4th	Ausco Biopharma 2017, Nantong (China), Series D	Developer of recombinant proteins	$407M	Goldstone Investment , CDH & 13 others	42/100
5th	Neovacs 1993, Paris (France), Public	CDMO focused on manufacturing of vaccines	$17.9M	Novartis Venture Fund, Truffle Capital & 5 others	41/100
6th	Yapanbio 2019, Hyderabad (India), Series B	Contract manufacturer of bio-therapeutics and vaccines	$13.4M	Piramal Group, Piramal Pharma Solutions	41/100
7th	HLL Biotech 2012, Chengalpattu (India), Unfunded	CDMO manufacturing vaccines	-	-	41/100
8th	Saudi Vax 2016, Riyadh (Saudi Arabia), Unfunded	CDMO focused on manufacturing of vaccines	-	-	41/100
9th	Primrose Bio 2023, San Diego (United States), Series B	Biotechnology company focusing on discovery, development, and manufacturing of new molecules	$15M	1315 Capital	40/100
10th	GC Biopharma 1967, Yongin si (South Korea), Unfunded	CDMO focused on manufacturing of vaccines	-	-	40/100
15th	Fina Biosolutions 2006, Rockville (United States), Seed	Conjugate vaccine solutions, bioconjugation services, and functionalized dextrans for emerging markets	$3M	NIH, IRDI Soridec Gestion & 2 others	31/100